UK launches programme to improve dementia clinical trial enrolment
An initiative to boost dementia clinical trial participation has been launched in the UK. The Dementia Trials Accelerator (DTA) has…
Central Nervous System
-
-
Alar Pharmaceuticals’ long-acting ketamine shows early potential in TRD
Alar Pharmaceuticals’ long-acting, ketamine-based therapy has shown early signs of symptom improvement in treatment-resistant depression (TRD) in a Phase I…
-
2025 dominated in ALS research
Amyotrophic lateral sclerosis (ALS) is a progressive disorder that affects motor neurons responsible for controlling voluntary muscle movement. As these…
-
AD/PD 2026: Roche’s prasinezumab shows promise on PD progression with five-year data
At the AD/PD 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, Roche showcased new five-year data…
-
AD/PD 2026: IRLAB’s pirepemat shows promise in reducing falls in Parkinson’s disease
At the AD/PD 2026 International Conference on Alzheimer’s and Parkinson’s Diseases, Integrative Research Laboratories Sweden AB (IRLAB) presented results from…
-
AD/PD 2026: AL-S Pharma’s AP‑101 data backs approach to target misfolded SOD1 in ALS
On 19 March, at the AD/PD 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, during a…
-
AD/PD 2026: Eisai highlights benefit of continued Leqembi treatment in early Alzheimer’s
In the current Alzheimer’s disease therapeutic space, the two approved disease-modifying therapies (DMTs) have differing treatment strategies despite both being…
-
AD/PD 2026: positive biomarkers support confirmatory trial for valiltramiprosate in MCI
On March 21, at the AD/PD 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, during a…
-
Aspen’s personalised Parkinson’s cell therapy to advance to Phase III
Aspen Neuroscience’s autologous, personalised stem cell therapy is set for a pivotal trial after it showed improved "ON" and "OFF"…
-
ArgenX highlights new Vyvgart data, demonstrating early disease control in ocular MG
On 26 February, ArgenX announced results from additional analyses of its blockbuster FcRn inhibitor Vyvgart in the Phase III Adapt…
